FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of organic chemistry, namely to heterocyclic compound of general formula (I) or to its pharmaceutically acceptable salt, acid salt or stereoisomer, where Y: NRa and N+R1R2X-; Z: bond, -(CH2)p, -CHOH, -CH=CH-, -C≡C-, -CONH- and -CO-; Rb: C1-C8 alkyl, C2-C8 alkenyl, C6-C10 aryl, -NR5R6,: , and
; with each alkyl, alkenyl and aryl, representing Rb, possibly, contains 1-3 substituents, selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6- and 7-membered heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, halogen, -OH, -NH2, -CN and -NO2; Rc: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, 9- and 10-membered bicyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; with C1-C6 alkyl, C2-C6 alkenyl C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C6-C10aryl, 5-, 6-, 7-, 8-membered monocyclic heterocyclyl and 9- and 10-membered bicyclic heterocyclyl, representing Rc, possibly contain 1-5 substituents, selected from the group, consisting of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C6 cycloalkyl, C4-C8 cycloalkenyla, halogen, -OH, -NH2, C6-C10 (A)(A')(A")(A'")aryl, (A)(A')(A")(A'")heterocyclyl, containing 1-3 heteroatom, selected from nitrogen, oxygen and sulphur, NR14R15, (CH2)pNR14R15, -CN, -NO2, oxo, -COOR14, SOR14, SO2R14, SO2NR14R15, NR15SO2R16, COR14, CONR14R15 and NR15COR16; with each (A), (A'), (A") and (A'")independently absent or representing C1-C4 alkyl, and each heterocyclyl (A)(A')(A")(A'")heterocyclyl is independently selected from the group, consisting of 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, and 9- and 10-membered bicyclico heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; the remaining radicals have values given in i.1;and on condition that, if Rc represents heterocyclyl, said heterocyclyl is bound directly through carbon atom of heterocyclyl ring. Invention also relates to particular compounds and to pharmaceutical composition based on formula (I) compound.
EFFECT: obtained are novel imidazopyrazine and imidazodiazepine derivatives, useful for prevention or treatment of disease or condition, severity of which is reduced by receptors to cannabinoids.
21 cl, 5 dwg, 4 tbl, 71 ex
Title | Year | Author | Number |
---|---|---|---|
PHTHALAZINE KETONE DERIVATIVE, METHOD OF OBTAINING THEREOF AND PHARMACEUTICAL APPLICATION | 2011 |
|
RU2564527C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
ANELLATED CABAMOYLAZAHETEROCYCLES, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARING | 2005 |
|
RU2281947C1 |
HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
TETRAHYDROQUINOLINE DERIVATIVES AND BASED PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT AND PREVENTION | 2005 |
|
RU2351592C2 |
METHODS FOR ACTIVATION OF CELLS-PRECURSORS/STEM CELLS | 2002 |
|
RU2309741C2 |
BICYCLIC PYRIDINE DERIVATIVES USEFUL AS FATTY ACID BINDING PROTEIN (FABP) 4 AND / OR 5 INHIBITOR | 2013 |
|
RU2648247C2 |
ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYLAMINES AND THEIR USING AS PHARMACEUTICAL PREPARATIONS | 2002 |
|
RU2301797C2 |
N-[(1H-PYRAZOL-1-YL) ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES, PRODUCING AND USING THEM AS P2Y12 ANTAGONISTS | 2011 |
|
RU2572593C2 |
Authors
Dates
2015-01-27—Published
2008-06-20—Filed